Skip to main content
Top
Published in: Neurological Sciences 1/2018

01-01-2018 | Brief Communication

Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study

Authors: Domiziana Rinaldi, Francesca Assogna, Michela Sforza, Stefania Tagliente, Francesco E. Pontieri

Published in: Neurological Sciences | Issue 1/2018

Login to get access

Abstract

Wearing-off refers to the predictable worsening of motor and sometimes non-motor symptoms of Parkinson’s disease occurring at the end of levodopa dose that improves with the next drug dose. Here, we investigated the efficacy of rasagiline on executive functions at the end of levodopa dose in patients displaying symptoms of wearing-off. Rasagiline was well-tolerated and produced a significant improvement at the Frontal Assessment Battery, together with improvement of motor symptoms at the end of levodopa dose. These results suggest that treatment of motor symptoms of wearing-off with rasagiline may be accompanied by improvement of executive functions, and further support the need for optimizing dopamine replacement therapy in fluctuating Parkinson’s disease patients.
Literature
1.
go back to reference Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin 25:841–849CrossRefPubMed Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin 25:841–849CrossRefPubMed
2.
go back to reference Stocchi F, Fossati C, Torti M (2015) Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 16:2231–2241CrossRefPubMed Stocchi F, Fossati C, Torti M (2015) Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 16:2231–2241CrossRefPubMed
3.
go back to reference Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GC, Cakmur R, Sahin HA, Emre M (2011) The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 26:1851–1858CrossRefPubMed Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GC, Cakmur R, Sahin HA, Emre M (2011) The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 26:1851–1858CrossRefPubMed
4.
go back to reference Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X, COMPASS-I Study Investigators (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14:205–212CrossRefPubMed Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X, COMPASS-I Study Investigators (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14:205–212CrossRefPubMed
5.
go back to reference Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMed Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMed
6.
go back to reference American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Publishing, Washington American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Publishing, Washington
7.
go back to reference Marconi R, Antonini A, Barone P et al (2012) Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurol Sci 33:585–593CrossRefPubMed Marconi R, Antonini A, Barone P et al (2012) Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurol Sci 33:585–593CrossRefPubMed
8.
go back to reference Spalletta G, Robinson RG, Cravello L, Pontieri FE, Pierantozzi M, Stefani A, Long JD, Caltagirone C, Assogna F (2014) The early course of affective and cognitive symptoms in de novo patients with Parkinson’s disease. J Neurol 261:1126–1132CrossRefPubMed Spalletta G, Robinson RG, Cravello L, Pontieri FE, Pierantozzi M, Stefani A, Long JD, Caltagirone C, Assogna F (2014) The early course of affective and cognitive symptoms in de novo patients with Parkinson’s disease. J Neurol 261:1126–1132CrossRefPubMed
9.
go back to reference Macdonald PA, Macdonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost JS, Monchi O (2011) The effects of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain 134:1447–1463CrossRefPubMed Macdonald PA, Macdonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost JS, Monchi O (2011) The effects of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain 134:1447–1463CrossRefPubMed
Metadata
Title
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study
Authors
Domiziana Rinaldi
Francesca Assogna
Michela Sforza
Stefania Tagliente
Francesco E. Pontieri
Publication date
01-01-2018
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 1/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-3123-2

Other articles of this Issue 1/2018

Neurological Sciences 1/2018 Go to the issue